Screen the entire global market — including names the crowd has left for dead — by quality, growth, returns and valuation.
Every subsector ranked on valuation, income, returns and leverage, computed from our own company financials with a book-value NAV proxy. Click a subsector for its full report.
We have researched Novo Nordisk A/S. The verdict, the fair value and the argument behind them are available to Premium members.
A PrimerIQ deep dive is a full research report on the company and everything around it — not a summary of one annual report. It covers:
You get a bear, base and bull case with the assumptions behind each, the price we think it is worth, and the specific things that would break the thesis.
Put a question to the analyst and get an answer grounded in this company's own filings and our research — "what breaks the thesis?", "how much of profit goes to interest?"
Included from Premium →It takes up to 3 hours and covers the filings, the competitors, the news, the wider industry, the economy it sits in, the regulatory backdrop, and a full model and a fair value with sensitivities. It runs in the background — we will let you know when it lands, so you do not need to keep this page open.
Annual financial statements as reported, going back as far as the data allows.
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
Who bought and sold, at what price, and how much of their own holding it was — from SEC Form 4 and UK PDMR notifications, with each insider's last-reported position and disclosed major holders.
This company has been valued on Reinvestment-consistent DCF, with a year-by-year forecast, the cost of capital built up from the risk-free rate, a bear/base/bull scenario set and a sensitivity grid. The fair value and the scenario range are on the Overview; the workings behind them — every driver, rate and sensitivity — are Premium.
The 6 investable Drug Manufacturers - General industry peers closest in size, largest first. Market caps are shown in USD so the set compares like with like; the multiples are currency-neutral. The median is taken across the PEERS only — it is what this company is being compared to — and per column, over the peers that actually report each measure.
| Company | Mkt cap (USD) | P/E | EV/FCF | P/B | ROIC | Op margin | Div yield |
|---|---|---|---|---|---|---|---|
| Novartis NOVN | $302.8bn | 21.4× | 17.9× | 6.6× | 22.0% | 31.1% | 2.6% |
| AstraZeneca AZN | $254.1bn | 24.3× | 23.5× | 5.2× | 15.9% | 23.4% | 2.0% |
| Amgen AMGN | $235.7bn | 27.0× | 34.7× | 27.2× | 14.4% | 24.7% | 2.5% |
| Novo Nordisk A/S NOVO-B | $206.4bn | 11.4× | 24.3× | 6.5× | 32.8% | 41.3% | 4.4% |
| GlaxoSmithKline GSKN | $205.4bn | 26.1× | — | 9.3× | 14.9% | 26.2% | 1.6% |
| Gilead Sciences GILD | $187.4bn | — | 21.7× | 8.3× | 21.7% | 34.0% | — |
| Pfizer PFE | $161.8bn | 37.3× | 24.8× | 1.9× | 3.8% | 12.0% | 3.4% |
| Peer median | $220.5bn | 26.1× | 23.5× | 7.4× | 15.4% | 25.4% | 2.5% |
A comparable set says what the market is paying for similar businesses today, not what any of them is worth. It is a cross-check on the model above, not a substitute for it.
A full deep-dive has been researched for this company: the business, the moat, the risks, the cost of capital and a bear/base/bull valuation, every figure tied back to the filings it came from.
Source documents straight from the database — click to read the raw filing or release — beside the issuer's own releases and dated events, newest first. Our read on what matters lives in Recent developments.
Upcoming and recent investor events — results, AGM, dividend and ex-dividend dates — from the company's own investor calendar.
Every place this issuer trades — the home listing, foreign cross-listings and depositary receipts (ADR/CDR/BDR), plus any separate share classes. The screener shows one canonical line per company; the rest live here.
| Listing | Exchange | Ticker | Currency | Price | Type |
|---|
Interactive price chart with the common technical-analysis overlays and indicators — moving averages, Bollinger Bands, volume, RSI and MACD — plus an at-a-glance momentum summary. Use the chart's own toolbar to add or remove studies, change timeframe, or search a different listing.
A note on method: PrimerIQ's research is built bottom-up from the filings — what a business earns and what it's worth. The charts below read price history, not the business; we include them because many investors want them, not because they drive our valuation. Treat them as one lens among several.
Relative strength percentile: 51 vs market, 52 vs industry. Momentum rank is a 0–100 percentile across 36,468 companies — one lens, not a valuation signal.
Charts and technical data by TradingView. Not investment advice.
The webcast audio itself, transcribed in full, with the structural signals the transcript text alone loses — how scripted rather than spontaneous the language is, where management hesitated longest, and which answers were most hedged.
Included from Premium →Select a filing on the left to read it here.
Select a filing to view its raw text.